Gene editing patent ruling sways fortune of biotech hopefuls

Gene editing patent ruling sways fortune of biotech hopefuls


In a highly anticipated decision that could sway the fortunes of a handful of biotechnology companies, the federal patent office has turned back a challenge to patents covering a widely used method for editing genes. The office's board of appeals ruled Wednesday that the Broad Institute of MIT and Harvard can keep patents it had been awarded for a technique called CRISPR that lets scientists alter DNA within cells.



from Biotech News